Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* McFarland John	2. Issuer Name and Ticker or Trading Symbol SYNAPTICS Inc [ SYNA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, General Counsel & Sec.
(Last) (First) (Middle) 1251 MCKAY DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 2/8/2021
(Street) SAN JOSE, CA 95131 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	2/8/2021		M		3000	A	$79.38	17860	D
Common Stock	2/8/2021		M		2725	A	$89.29	20585	D
Common Stock	2/8/2021		M		3000	A	$76.81	23585	D
Common Stock	2/8/2021		M		3000	A	$85.69	26585	D
Common Stock	2/8/2021		M		2725	A	$73.31	29310	D
Common Stock	2/8/2021		M		2725	A	$71.55	32035	D
Common Stock	2/8/2021		S		3100	D	$117.4691 ⁽¹⁾	28935	D
Common Stock	2/8/2021		S		8190	D	$118.6601 ⁽²⁾	20745	D
Common Stock	2/8/2021		S		1674	D	$120.4336 ⁽³⁾	19071	D
Common Stock	2/8/2021		S		4211	D	$121.4666 ⁽⁴⁾	14860	D
Common Stock	2/9/2021		M		2725	A	$51.95	17585	D
Common Stock	2/9/2021		M		3575	A	$52.57	21160	D
Common Stock	2/9/2021		M		3575	A	$54.36	24735	D
Common Stock	2/9/2021		M		3575	A	$54.77	28310	D
Common Stock	2/9/2021		S		1400	D	$121.4081 ⁽⁵⁾	26910	D
Common Stock	2/9/2021		S		4328	D	$122.591 ⁽⁶⁾	22582	D
Common Stock	2/9/2021		S		7722	D	$123.0166 ⁽⁷⁾	14860	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$79.38	2/8/2021		M			3000	⁽⁸⁾	7/31/2022	Common Stock	3000	$0.00	0	D
Employee Stock Option (Right to Buy)	$89.29	2/8/2021		M			2725	⁽⁹⁾	10/23/2022	Common Stock	2725	$0.00	0	D
Employee Stock Option (Right to Buy)	$76.81	2/8/2021		M			3000	⁽¹⁰⁾	1/30/2022	Common Stock	3000	$0.00	0	D
Employee Stock Option (Right to Buy)	$85.69	2/8/2021		M			3000	⁽¹¹⁾	4/24/2022	Common Stock	3000	$0.00	0	D
Employee Stock Option (Right to Buy)	$73.31	2/8/2021		M			2725	⁽¹²⁾	1/29/2023	Common Stock	2725	$0.00	0	D
Employee Stock Option (Right to Buy)	$71.55	2/8/2021		M			2725	⁽¹³⁾	4/29/2023	Common Stock	2725	$0.00	0	D
Employee Stock Option (Right to Buy)	$51.95	2/9/2021		M			2725	⁽¹⁴⁾	7/29/2023	Common Stock	2725	$0.00	0	D
Employee Stock Option (Right to Buy)	$52.57	2/9/2021		M			3575	⁽¹⁵⁾	10/28/2023	Common Stock	3575	$0.00	0	D
Employee Stock Option (Right to Buy)	$54.36	2/9/2021		M			3575	⁽¹⁶⁾	1/27/2024	Common Stock	3575	$0.00	0	D
Employee Stock Option (Right to Buy)	$54.77	2/9/2021		M			3575	⁽¹⁷⁾	4/28/2024	Common Stock	3575	$0.00	0	D

Explanation of Responses:
(1)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.92 to $117.79, inclusive. The reporting person undertakes to provide to Synaptics Incorporated (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(2)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118 to $118.94, inclusive. The reporting person undertakes to provide to Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.92 to $120.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(4)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.928 to $121.740, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.95 to $121.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(6)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122 to $122.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(7)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123 to $123.14, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(8)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the July 31, 2015 date of grant, until fully vested on July 31, 2018.
(9)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the October 23, 2015 date of grant, until fully vested on October 23, 2018.
(10)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the January 30, 2015 date of grant, until fully vested on January 30, 2018.
(11)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the April 24, 2015 date of grant, until fully vested on April 24, 2018.
(12)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the January 29, 2016 date of grant, until fully vested on January 29, 2019.
(13)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the April 29, 2016 date of grant, until fully vested on April 29, 2019.
(14)	1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the July 29, 2016 date of grant, until fully vested on July 29, 2019.
(15)	33% of the total number of shares subject to the option vested and became exercisable one year following the vesting commencement date of October 28, 2016, with the remaining 2/3rds vesting quarterly until fully vested on October 28, 2019.
(16)	33% of the total number of shares subject to the option vested and became exercisable one year following the vesting commencement date of January 27, 2017,with the remaining 2/3rds vesting quarterly until fully vested on January 27, 2020.
(17)	33% of the total number of shares subject to the option vested and became exercisable one year following the vesting commencement date of April 28, 2017, with the remaining 2/3rds vesting quarterly until fully vested on April 28, 2020.

Remarks:
The reporting person is SVP, General Counsel & Secretary.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
McFarland John 1251 MCKAY DRIVE SAN JOSE, CA 95131			SVP, General Counsel & Sec.